Iovance Biotherapeutics argues that there is a meaningful opportunity here of more than 8,000 patients diagnosed annually in ...

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

In the highly regulated world of life sciences, quality isn’t a box to check—it’s a business imperative. For global ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

The news is the latest example of the biotech industry's struggles in the Bay Area.

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...

Biotech executives, investors, and R&D leaders all face the same burning question in 2026: How do we scale breakthroughs from ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Integrated consulting approach streamlines pathway from concept to commercialization NEW YORK, NY, UNITED STATES, April ...

The companies Earendil Labs, Teva Pharmaceuticals, and Solid Biosciences bagged the biggest biotech funding rounds overall in ...